Evidence map›Paper›PMID 36584835›Full record

Trial reportAmerican journal of ophthalmology2023

SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes.

Ingrid U Scott, Neal L Oden, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, SCORE2 Investigator Group

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Ingrid U ScottFrom the Departments of Ophthalmology and Public Health Sciences (I.U.S.), Penn State College of Medicine, Hershey, Pennsylvania, USA.
Neal L OdenFrom the Departments of Ophthalmology and Public Health Sciences, Emmes (N.L.O., P.C.V.), Rockville, Maryland, USA.
Paul C VanVeldhuisenFrom the Departments of Ophthalmology and Public Health Sciences, Emmes (N.L.O., P.C.V.), Rockville, Maryland, USA. Electronic address: score2@emmes.com.
Michael S IpDoheny Eye Institute (M.S.I.), University of California, Los Angeles, California.
Barbara A BlodiUniversity of Wisconsin Fundus Photograph Reading Center (B.A.B.), Madison, Wisconsin, USA.
SCORE2 Investigator Group
Emmes (United States) · USPenn State Milton S. Hershey Medical Center · USUniversity of California, Los Angeles · USUniversity of Wisconsin Foundation · US

Funding

SCORE2 Comparative Trial (SCT)U10EY023533 · NEI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SCOTT, INGRID U · 2013 to 2018
$7.4M
SCORE2 Comparative Trial (SCT)U10EY023529 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2013 to 2018
$6.8M
The SCORE2 Long-Term Follow-Up (SCORE2 LTF)UG1EY023533 · NEI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SCOTT, INGRID U · 2019 to 2021
$3.7M
SCORE2 Comparative Trial (SCT)U10EY023521 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI BLODI, BARBARA A · 2013 to 2018
$1.8M
NEI NIH HHS U10 EY023521NEI NIH HHS U10 EY023529NEI NIH HHS U10 EY023533NEI NIH HHS UG1 EY023533
6 · The paper itself

Abstract

purposeTo investigate the relationship of anti-vascular endothelial growth factor (anti-VEGF) treatment discontinuation with baseline factors and outcomes in eyes treated initially with aflibercept or bevacizumab for macular edema from central or hemiretinal vein occlusion.

designLong-term follow-up after a randomized clinical trial from 64 US centers.

methodsAnalysis included 150 SCORE2 Month 60 completers classified into 3 groups: discontinued treatment early, treated intermittently, and treated continuously. Outcomes included visual acuity (VA) and central subfield thickness (CST).

resultsPatients who discontinued treatment early were younger (60.9 years, vs 66.7 and 70.5 for the treated intermittently and treated continuously groups; P = .001), and 17.4% were Black, compared to 19.5% and 4.7% for the treated intermittently and treated continuously groups (P = .006). At Month 60, the discontinued treatment early group had a higher proportion with complete resolution of macular edema (69.6%) than those treated intermittently (15.0%) and treated continuously (15.7%) (P < .001). Least-squares means analyses over follow-up demonstrated that the discontinued treatment early group had a lower mean CST (257 µm) than the treated intermittently (CST = 303 µm, P = .02) and treated continuously (CST = 300 µm, P = .01) groups.

conclusionsCompared to those treated continuously, those who discontinued treatment early were younger and more likely Black. The discontinued treatment early group had a higher proportion with complete resolution of macular edema at Month 60, and a lower mean CST over follow-up, but not better VA, than the treated continuously and treated intermittently groups. Results support the need for continued monitoring and individualized treatment for patients treated with anti-VEGF for macular edema from central or hemiretinal vein occlusion.

Indexed as

Macular EdemaRetinal Vein OcclusionAngiogenesis InhibitorsBevacizumabHumansIntravitreal InjectionsReceptors, Vascular Endothelial Growth FactorTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsBevacizumabReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor A

Identifiers

PMID36584835
PMCPMC10038860
OpenAlexW4313339962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.